Factors associated with treatment for latent tuberculosis in persons living with HIV/AIDS

Aquino, Daniela Silva de; Moura, Líbia Cristina Rocha Vilela; Maruza, Magda; Silva, Adriana Paula da; Ximenes, Ricardo Arraes de Alencar; Lacerda, Heloísa Ramos; Miranda Filho, Demócrito de Barros; Albuquerque, Maria de Fátima Pessoa Militão de.
Artículo en Portugués | ARCA | ID: arc-20964

Documentos relacionados

  1. Treatment of latent tuberculosis infection in patients receiving biologic agents.
  2. Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion.
  3. Editorial Commentary: Do We Have Strategies to Improve the Preventive Treatment of Latent Tuberculosis Infection?
  4. Trials of Tuberculosis-Preventive Therapy in People with HIV Infection.
  5. Reply to Swindells <i>et al.</i>: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection.
  6. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
  7. Patient-Reported Barriers to Treatment Initiation and Completion for Latent Tuberculosis Infection Among Patients Within a Large Integrated Health Care System in Southern California.
  8. Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients.
  9. A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators.
  10. US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.